petosemtamab
merus
['petosemtamab', 'merus ']
we are excited to share the interim clinical data on petosemtamab monotherapy at #aacr23, with a 37% orr per investigator review in previously treated #hnscc. see the presentation with safety and efficacy from a 2/1/23 cutoff here.
#closeinoncancer 
Clinical-stage oncology company developing Biclonics® bispecific antibody therapeutics. Please see our Community Guidelines: https://t.co/qN9crK04bE